Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VitaliThy phase 3 study of subcutaneous efgartigimod PH20 in Graves' disease inadequately controlled with antithyroid drugs
2025-523333-26-00Phase 3Authorised
- Sponsor
- argenx
- Start
- Aug 2026
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of efgartigimod alfa and Placebo-COD Research Private Ltd in Graves' disease (2 arms), sponsored by argenx. Primary endpoint: Percentage of participants who are euthyroid off antithyroid drugs at week 24 in part A. Planned start Aug 2026; status: authorised.
02
Drugs
efgartigimod alfaPlacebo-COD Research Private Ltd
03
Conditions
Graves' disease
Beyond the preview
Go deeper on 2025-523333-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523333-26-00.